Replimune Group REPL Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Replimune Group in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Replimune Group's business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Replimune Group's business segments — operating income (loss)?
- Replimune Group (REPL) reported business segments — operating income (loss) of -$71.87M in Q4 2025.
- How has Replimune Group's business segments — operating income (loss) changed year-over-year?
- Replimune Group's business segments — operating income (loss) decreased by 8.9% year-over-year, from -$66.02M to -$71.87M.
- What does business segments — operating income (loss) mean?
- Calculated as total revenue minus total operating expenses, representing the core profitability of the business segment before financing and tax considerations. For clinical-stage biotechnology firms, this is typically negative, reflecting the heavy investment in R&D relative to commercial revenue generation.